Type 2 diabetes
Conditions
Interventions
The CGM examination is carried out at least 14 days after administering liraglutide. Canagliflozin is changed to dulaglutide when the first CGM examination end.
The CGM examination is carried out at l
Sponsors
Kitasato University School of Pharmacy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients using Glucagon-Like Peptide 1 Receptor Agonist or the patients who judged a physician to need use of the Glucagon-Like Peptide 1 Receptor Agonist newly.
Exclusion criteria
Exclusion criteria: Patients with diabetic nephropathy more than stage 4 or with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) were excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic control is estimated as the mean blood glucose (MBG), the area under the glucose curve above 10.0mmol/L (area under the curve [AUC]>10), and the percentage of time above 10.0mmol/L (t>10).The AUC is calculated using the trapezoidal method. Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE). Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L. Severe hypoglycemia is defined as a sensor value of <2.8mmol/L. | — |
Countries
Japan
Contacts
Public ContactInoue Gaku
Kitasato University School of Pharmacy Center for Clinical Pharmacy and Clinical Sciences
Outcome results
None listed